BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Market Closed - BOERSE MUENCHEN 20:46:44 28/06/2024 BST | ||
| 1,104 EUR | +0.59% |
|
| Current month | +8.27% | ||
| 1 month | +10.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 1,104 | +0.59% |
| 27/06/24 | 1,098 | +0.03% |
| 26/06/24 | 1,097 | -0.09% |
| 25/06/24 | 1,098 | +0.34% |
| 24/06/24 | 1,095 | +0.53% |
Real-time BOERSE MUENCHEN
Last update June 28, 2024 at 08:46 pm
More quotesStatic data
| Product type | Bonus- und Teilschutz-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD3TA4 |
| ISIN | DE000HD3TA40 |
| Date issued | 18/03/2024 |
| Strike | 1,150 $ |
| Maturity | 20/12/2024 (175 Days) |
| Parity | 1 : 1 |
| Emission price | 894.5 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,104 € |
|---|---|
| Lowest since issue | 834 € |
| Spread | 0.4 € |
| Spread % | 0.04% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Certificates
- Certificat
